Biowaiver monographs for immediate release solid oral dosage forms: Ranitidine hydrochloride

Journal of Pharmaceutical Sciences

Volumn 94, Issue 8, 2005, Pages 1617-1625

  Kortejarvi H ^a   Yliperttula, M ^a   Dressman, J B ^b   Junginger, H E ^c   Midha, K K ^d   Shah, V P ^e   Barends, D M ^f  

^a ORION CORPORATION   (Finland)

^b GOETHE UNIVERSITY   (Germany)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Absorption; Biopharmaceutics Classification System (BCS); Permeability; Ranitidine; Solubility

Indexed keywords

ATENOLOL; CALCIUM PHOSPHATE DIBASIC; CARBOXYMETHYLCELLULOSE; CASTOR OIL; CELLULOSE; CITRIC ACID TRIETHYL ESTER; DEXTRAN; DODECYL SULFATE SODIUM; ESOFEX; ETHYL CELLULOSE; EXCIPIENT; GLUCOSE; GLUCOSE POLYMER; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYPROPYLCELLULOSE; JUNIZAC; MACROGOL 400; MAGNESIUM STEARATE; METFORMIN; METOPROLOL; POLYMETHACRYLIC ACID; POLYSORBATE; POVIDONE; RAN LICH; RANI NERTON; RANI PUREN; RANIBERL; RANIBETA; RANIBLOC; RANICUR; RANICUX; RANIL; RANIMERCK; RANIMEX; RANIPROTECT; RANITAB; RANITIC; RANITIDIN ACIS; RANITIDIN ISIS; RANITIDIN RATIOPHARM; RANITIDIN SAAR; RANITIDIN SANDOZ; RANITIDIN STADA; RANITIDINE; RANITIDOC; RANIXAL; SHELLAC; SILICON DIOXIDE; SIMETHICONE; SOYBEAN OIL; STARCH GLYCOLATE SODIUM; TALC; TRIACETIN; WAX;

DOSE RESPONSE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG EXCRETION; DRUG FECES LEVEL; DRUG INDICATION; DRUG METABOLISM; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG URINE LEVEL; DUODENUM ULCER; HELICOBACTER INFECTION; HUMAN; PARTITION COEFFICIENT; PKA; REVIEW; SIDE EFFECT; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

EID: 25444489870     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20392     Document Type: Note

References (51)

1. Vogelpoel H, Welink J, Amidon GL, Junginger HE, Midha KK, Moller H, Oiling M, Shah VP, Barends DM. 2004. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol. J Pharm Sci 93:1945-1956.
2. Martindale. 2004. In: Sweetman S, editor. Martindale: The complete drug reference. London UK: Pharmaceutical Press. Electronic version, Thomson MICROMEDEX, Greenwood Village, Colorado.
3. Shen J, Lee D, Mc Keag RG. 1995. Bioequivalence of two forms of ranitidine. New Zealand Pharmacy Oct.: 24-25.
4. Carey PF, Martin LE, Owen PE. 1981. Determination of ranitidine and its metabolites in human urine by reversed-phase ion-pair high-performance liquid chromatography. J Chromatogr 225:161-168.
5. ACD/Labs Software™. Advanced Chemistry Development Inc., www.acdlabs.com.
6. Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. 1982. Ranitidine: a review of its pharmacology and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 24:267-303.
7. th edn. McGraw-Hill. Medical publishing division.
8. WHO. 2003. WHO Model List of Essential Medicines 13th Ed. www.who.int/medicines/organization/par/edl/expcom13/eml13_en.doc.
9. Rote Liste® Service GmbH FMG. 2004. Arzneimittelverzeichnis fur Deutschland. In Verlag EG, Aulendorf, Germany, www.rote-liste.de.
10. www.nam.fi/laakeinformaatio/index.html.
11. www.cbg-meb.nl.
12. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). 2000. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System.
13. Committee for Proprietary Medicinal Products (CPMP). 2001. Note for Guidance on the Investigation of Bioavailability and Bioequivalence.
14. Bogues K, Dixon GT, Fowler P, Jenner WN, Maconochie JG, Martin LE, Willoughby BA. 1980. Pharmacokinetics and bioavailability of ranitidine in humans. Br J Clin Pharmacol 73:275P-276P.
15. Garg DC, Weidler DJ, Baltodano N, Eshelman FN. 1981. Pharmacokinetics of ranitidine, a new histamine H2-receptor blocker. Br J Clin Pharmacol 29: 247-248.
16. Chau NP, Zech PY, Pozet N, Hadj-Aissa A. 1982. Ranitidine kinetics in normal subjects. Clin Pharmacol Ther 31:770-774.
17. Martin LE, Bell JA, Carey PF, Dallas FAA, Dixon GT, Jenner WN. 1982. A review of pharmacokinetics and metabolism of ranitidine in animals and man. Med Publ Found Symp Ser 5:23-31.
18. Garg DC, Weidler DJ, Eshelman FN. 1983. Ranitidine bioavailability and kinetics in normal male subjects. Clin Pharmacol Ther 33:445-452.
19. Mignon M, Chau NP, Nguyen-Phuoc BK, Sauvage M, Leguy F, Bonfils S. 1982. Ranitidine upon meal-induced gastric secretion: oral pharmacokinetics and plasma concentration effect relationships. Br J Clin Pharmacol 14:187-193.
20. Woodings EP, Dixon GT, Harrison C, Carey P, Richards DA. 1980. Ranitidine-a new H2-receptor antagonist. Gut 21:187-191.
21. Van Hecken AM, Tjandramaga TB, Mullie A, Verbesselt R, De Schepper PJ. 1982. Ranitidine: single dose pharmacokinetics and absolute bioavailability in man. Br J Clin Pharmacol 14:195-200.
22. Klotz U, Walker S. 1990. Biliary excretion of H2-receptor antagonists. Eur J Clin Pharmacol 39: 91-92.
23. Williams MF, Dukes GE, Heizer W, Han Y-H, Hermann DJ, Lampkin T, Hak LJ. 1992. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm Res 9:1190-1194.
24. Pithavala YK, Heizer WD, Parr AF, O'Connor-Semmes RL, Brouwer KL. 1998. Use of the InteliSite capsule to study ranitidine absorption from various sites within the human intestinal tract. Pharm Res 15:1869-1875.
25. Mc Neil JJ, Mihaly GW, Anderson A, Marshall AW, Smallwood RA, Louis WJ. 1981. Pharmacokinetics of the H2-reeceptor antagonist ranitidine in man. Br J Clin Pharmacol 12:411-415.
26. Gan LS, Hsyu PH, Pritchard JF, Thakker D. 1993. Mechanism of intestinal absorption of ranitidine and ondansetron: transport across Caco-2 cell monolayers. Pharm Res 10:1722-1725.
27. Lee K, Thakker DR. 1999. Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers. J Pharm Sci 88:680-687.
28. Collet A, Higgs NB, Sims E, Rowland M, Warhurst G. 1999. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. J Pharmacol Exp Ther 288:171-178.
29. Walter E, Janich S, Roessler BJ, Hilfinger JM, Amidon GL. 1996. HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. J Pharm Sci 85:1070-1076.
30. Yazdanian M, Briggs K, Jankovsky C, Hawi A. 2004. The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. Pharm Res 21:293-299.
31. Takamatsu N, Kim ON, Welage LS, Idkaidek NM, Hayashi Y, Barnett J, Yamamoto R, Lipka E, Lennernas H, Hussain A, Lesko L, Amidon GL. 2001. Human jejunal permeability of two polar drugs: cimetidine and ranitidine. Pharm Res 18: 742-744.
32. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm Res 17:1456-1460.
33. Lebert PA, Mac Leod SM, Mahon WA, Soldin SJ, Vandenberghe HM. 1981. Ranitidine kinetics and dynamics. I. Oral dose studies. Clin Pharmacol Ther Oct.: 539-544.
34. Gleiter CH, Klotz U, Kuhlmann J, Blume H, Stanislaus F, Harder S, Paulus H, Poethko-Muller C, Holz-Slomczyk M. 1998. When are bioavailability studies required? A German proposal. J Clin Pharmacol 38:904-911.
35. Bundesinstitut für Arzneimittel und Medizinprodukte. 2003. BundesAnzeiger. March 25:5296.
36. Rege BD, Yu LX, Hussain AS, Polli JE. 2001. Effect of common excipients on Caco-2 transport of low-permeability drugs. J Pharm Sci 90:1776-1786.
37. Aungst BJ. 2000. Intestinal permeation enhancers. J Pharm Sci 89:429-442.
38. Koch KM, Parr AF, Tomlinson JJ, Sandefer EP, Digenis GA, Donn KH, Powell JR. 1993. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm Res 10:1027-1030.
39. Basit AW, Lacey LF. 2001. Colonic metabolism of ranitidine: implications for its delivery and absorption. Int J Pharm 227:157-165.
40. Schulze JD, Waddington WA, Eli PJ, Parsons GE, Coffin MD, Basit AW. 2003. Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. Pharm Res 20:1984-1988.
41. USP 27 - NF 22. 2004. The United States Pharmacopeia - The National Formulary, ed., Rockville MD 2085: The United States Pharmacopeial Convention Inc.
42. Ali SL, Meins J, Schmitt E, Theins C. 1998. Ranitidinpräparate im Vergleich. Pharmazie 40: 58-69.
43. Cappola ML. 2001. A better dissolution method for ranitidine tablets USP. Pharmaceutical Development and Technology 6:11-17.
44. Yu LX, Wang JT, Hussain AS. 2002. Evaluation of USP apparatus 3 for dissolution testing of immediate-release products. AAPS PharmSci 4:E1.
45. Polli JE. 1997. In vitro-in vivo relationships of several "immediate" release tablets containing a low permeability drug. Adv Exp Med Biol 423:191-198.
46. Kaus LC, Gillespie WR, Hussain AS, Amidon GL. 1999. The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. Pharm Res 16:272-280.
47. Balan G, Timmins P, Greene DS, Marathe PH. 2001. In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. J Pharm Sci 90:1176-1185.
48. Cheng CL, Yu LX, Lee HL, Yang CY, Lue CS, Chou CH. 2004. Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. Eur J Pharm Sci 22:297-304.
49. Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 19:921-925.
50. Blume HH, Schug BS. 1999. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? Eur J Pharm Sci 9:117-121.
51. Dressman JB, Butler J, Hempenstall J, Reppas C. 2001. The BCS: Where do we go from here? Pharm Techol Jul.: 68-76.